To compare the short term, long term and nutritional benefits of the Metanx vs placebo in patients with Diabetic Peripheral Neuropathy


Contact Principal Investigator for Information


Patients ages 25-80 that have a diagnosis of diabetic peripheral neuropathy for at least 6 months but less than 7 years will be enrolled.  Patients will be randomly assigned to Metanx or placebo once enrolled.  Metanx is classified as a medical food.  Patients will complete quality of life questionnaires, have lab samples taken, skin punch biopsy  and undergo EKG's at designated visits.

Interested in more information? Contact Us:

Jason Milligan, M.D., Principal Investigator
(318) 212-8130

IRB: Copernicus
IRB Number:
Trial Type: Drug
Sponsor: PamLab